Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Genzyme, a Sanofi Company | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This is a randomized, controlled, single center study to evaluate the efficacy of Thymoglobulin induction therapy in combination with Mycophenolate Mofetil, tacrolimus, and steroids in the prevention of CAV. Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 6 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4 hours.
Mechanistic assays (T-reg cells, Lym subsets, B cell subsets, IL-1b, cytokines, TGFb, IL-21 to be drawn at Pre-transplant, 3, 6, 12 months post-transplant) will also be performed.
All patients will be followed and monitored according to standard of care protocols for heart transplant recipients at our center.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Thymoglobulin® | Active Comparator | Thymoglobulin® (Genzyme) [rabbit anti-thymocyte globulin (ATG)] is a purified pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes. This immunosuppressive product contains polyclonal cytotoxic antibodies directed against antigens expressed on human T-lymphocytes. Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 6 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4 hours. In addition, there will be maintenance doses of mycophenolate mofetil, tacrolimus, sirolimus, and cumulative dose of corticosteroids at 12 months post-transplantation |
|
| No induction therapy | No Intervention | Patients qualifying for the study will be randomized before the transplantation surgery in a 1:1 ratio to either Thymoglobulin® or no treatment. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Thymoglobulin | Drug | Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 8 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4-8 hours. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Composite Efficacy Failure at 12 Months | Composite efficacy failure is defined as development of de novo donor specific antibodies (measured by standardized alloantibody testing by Luminex and control sera, characterizing kinetics, specificities and relative binding strength) and ischemia on endomyocardial biopsy (characterized on biopsy by myocyte necrosis and/or regions of myocyte dropout) at 12 months post-transplant. | 12 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in immune cell profiles | Correlations between significant changes in immune cell profiles and biomarkers, and their relation to any significant differences in clinical outcomes | 12 months |
| Changes in biomarkers |
Not provided
Inclusion Criteria for Study Entry:
Exclusion Criteria for Study Entry:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jon Kobashigawa, MD | Director | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kaiser Permanente Los Angeles Medical Center | Los Angeles | California | 90027 | United States | ||
| Cedars-Sinai Medical Center |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Aug 17, 2023 | Nov 21, 2023 | Prot_001.pdf |
Not provided
| ID | Term |
|---|---|
| C512542 | thymoglobulin |
| D009173 | Mycophenolic Acid |
| D016559 | Tacrolimus |
| D020123 | Sirolimus |
| D000305 | Adrenal Cortex Hormones |
| ID | Term |
|---|---|
| D002208 | Caproates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Mycophenolate Mofetil | Drug | 3.0 grams divided bid begun post-transplant, either IV or po as tolerated by patient. Initial dose must be given within 24 hours post-transplant. Dosing will be titrated based on recipient's body size and any adverse side effects |
|
| Tacrolimus | Drug | Doses of 1-4 mg bid either IV or po will be prescribed to achieve a target trough level of 10-15 ng/mL before post-operative day number 5. Target trough levels are 10-15 ng/mL for post-operative days #1-30, 8-12ng/mL days#31-60 and 5-10 ng/mL thereafter. |
|
| Sirolimus | Drug | Maintenance doses of sirolimus at 12 months post-transplantation |
|
| Corticosteroids | Drug | 125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone at 1.0 mg/kg/day po divided into bid doses that are rounded off to the next higher 5 mg increment. For example, a 76 kg person would should be dosed at 38 mg po bid, which rounded off to the next 5 mg increment would be 40 mg po bid. (Equivalent dosing via an alternative route may be used if pos not tolerated or contraindicated). Prednisone will be tapered by 10 mg qd until the dose of 10 mg po bid is reached. |
|
Correlations between significant changes in biomarkers and their relation to any significant differences in clinical outcomes
| 12 months |
| Number of patients who experience rejection | Number of patients who experience acute cellular, antibody-mediated, hemodynamic compromise, and any-treated rejection within first 12 months after transplantation/ | 12 months |
| Number of episodes per patient | Number of acute cellular, antibody-mediated, hemodynamic compromise and any-treated rejection episodes per patient within the first 12 months post-transplantation | 12 months |
| First rejection by ISHLT biopsy grading scale | First acute cellular, antibody-mediated, hemodynamic compromise, and any-treated rejection by the ISHLT biopsy grading scale in the first 12 months post-transplantation | 12 months |
| Time to first rejection | Time to first acute cellular, antibody-mediated, hemodynamic compromise, and any-treated rejection within the first 12 months | 12 months |
| Incidence of primary graft dysfunction (PGD) | The incidence of Primary Graft Dysfunction(PGD) in the first 24 hours post-transplant | first 24 hours post-transplant |
| Patient and graft survival | Patient and graft survival at 12 months post-transplantation | 12 months |
| Types of patients with fatal infectious complications | The types of patients with fatal infectious complications (especially CMV infection) within the first 12 months post-transplantation | 12 months |
| Number of patients with fatal infectious complications | The number of patients with fatal infectious complications (especially CMV infection) within the first 12 months post-transplantation | 12 months |
| Types of patients with non-fatal infectious complications | Types of patients with non-fatal infectious complications (especially CMV infection) within the first 12 months post-transplantation | 12 months |
| Number of patients with non-fatal infectious complications | Number of patients with non-fatal infectious complications (especially CMV infection) within the first 12 months post-transplantation | 12 months |
| Freedom from development of circulating antibodies | Freedom from the development of circulating antibodies within the first 12 months post transplantation, where circulating antibodies include donor specific antibodies (DSA), non-specific antibodies, and non-human leukocyte antigen antibodies | 12 months |
| Change in coronary maximal intimal thickness | Change in coronary maximal intimal thickness at matched sites by intravascular ultrasound at 12 months | 12 months |
| Change in coronary intimal area | Change in coronary intimal area at matched sites by intravascular ultrasound at 12 months | 12 months |
| Change in coronary intimal volume | Change in coronary intimal volume at matched sites by intravascular ultrasound at 12 months | 12 months |
| Change in coronary vessel area | Change in coronary vessel area at matched sites by intravascular ultrasound at 12 months | 12 months |
| Change in coronary intimal index | Change in coronary intimal index at matched sites by intravascular ultrasound at 12 months | 12 months |
| Change in coronary percent atheroma volume | Change in coronary percent atheroma volume at matched sites by intravascular ultrasound at 12 months | 12 months |
| Maintenance doses of mycophenolate mofetil, tacrolimus, sirolimus, and dose of corticosteroids | Maintenance doses of mycophenolate mofetil, tacrolimus, sirolimus, and cumulative dose of corticosteroids at 12 months post-transplantation | 12 months |
| Number of hospital days per patient | Number of hospital days per patient, both during the transplant period and during the post-transplant period at 3 months, 6 months, and 1 year | 3 months, 6 months, 12 months |
| Number of patients requiring hospitalization | Number of patients requiring hospitalization by 3 months, by 6 months, or by 1 year post-transplantation | 3 months, 6 months, 12 months |
| Death/Re-transplant | To describe between treatment groups the incidence of the composite primary endpoint of death/re-transplant at 12 months post-transplantation | 12 months |
| Hemodynamic compromise rejection | To describe between treatment groups the incidence of the composite primary endpoint of hemodynamic compromise rejection at 12 months post-transplantation. This is an ejection fraction of ≤ 30% or a 0.20 absolute decrease from baseline, and the need for inotropic agents OR a fractional shortening ≤ 20% or a 25% decrease from baseline, and the need for inotropic agents PLUS need for inotropic agents due to a Cardiac Index (CI) < 2.0 L/min/m2 or a 25% decrease from baseline | 12 months |
| Graft dysfunction | To describe between treatment groups the incidence of the composite primary endpoint of graft dysfunction (ejection fraction less than or equal to 40% by echocardiography)at 12 months post-transplantation | 12 months |
| Cellular rejection | To describe between treatment groups the incidence of the composite primary endpoint of biopsy proven cellular rejection ≥2R at 12 months post-transplantation | 12 months |
| Antibody mediated rejected | To describe between treatment groups the incidence of the composite primary endpoint of biopsy proven antibody mediated rejection ≥AMR1 at 12 months post-transplantation | 12 months |
| Cardiac Allograft Vasculopathy (CAV) | To describe between treatment groups the incidence of cardiac allograft vasculopathy (CAV) (defined as a change ≥0.5mm in maximal intimal thickness (MIT) of the coronary arteries by intravascular ultrasound at 12 months as compared to baseline) | 12 months |
| Any treated rejection | To describe between treatment groups any treated rejection at 12 months | 12 months |
| Los Angeles |
| California |
| 90048 |
| United States |
| D005227 |
| Fatty Acids |
| D008055 | Lipids |
| D018942 | Macrolides |
| D007783 | Lactones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |